Articles
ICH S10 phototoxicity testing: the 3T3 NRU test and melanin binding
Phototoxicity is a light-induced toxic reaction: a compound absorbs ultraviolet or visible light, and the absorbed energy damages the tissue in which it sits, typically the skin or the eye. For a drug candidate, this risk has to be considered before patients are exposed to sunlight. The ICH S10 guideline sets out how, and the 3T3 NRU phototoxicity test described in OECD Test Guideline 432 is one of the main in vitro tools available to answer the question.
This article explains when ICH S10 calls for photosafety testing, how the 3T3 NRU phototoxicity test works and is interpreted, and how a complementary melanin binding assay can help characterise a compound that may accumulate in pigmented tissues.
Highlights
When does ICH S10 require photosafety testing?
ICH S10 takes a stepwise approach. Not every drug candidate needs a phototoxicity test: the assessment starts from the photochemical properties of the molecule and from where it distributes in the body. A photosafety concern is generally considered when a compound:
- absorbs light between 290 and 700 nm, with a molar extinction coefficient above 1000 L·mol⁻¹·cm⁻¹;
- becomes reactive after absorbing light, for example by generating reactive oxygen species;
- reaches light-exposed tissues, mainly the skin and the eye.
When these conditions cannot be ruled out, experimental data are needed. The 3T3 NRU phototoxicity test is a validated, standardised in vitro method, and is widely used as an experimental step in the photosafety assessment of pharmaceuticals.
Key figures
290–700 nm
Wavelength range considered by ICH S10
8
Test concentrations, in triplicate
5 J/cm²
UV-A dose delivered to the irradiated plate
PIF
Photo-Irritation Factor, the key readout
How the 3T3 NRU phototoxicity test works
The 3T3 NRU phototoxicity test measures the cytotoxicity of a compound in the presence and in the absence of a non-cytotoxic dose of simulated sunlight. Balb/c 3T3 mouse fibroblasts are exposed to a range of concentrations of the test item on two plates. One plate is irradiated with UV-A, the other is kept in the dark. Cell viability is then measured by the uptake of neutral red, a vital dye that accumulates in the lysosomes of living cells. If the compound is markedly more cytotoxic under light than in the dark, it has phototoxic potential.
At GenEvolutioN, the test can be performed under GLP, following OECD 432 (2019) and ICH S10:
- Test system: Balb/c 3T3 fibroblasts.
- Light source: Atlas Suntest CPS+ solar simulator, filtered against UV-B emission.
- Irradiation: 5 J/cm² of UV-A, i.e. approximately 30 to 60 minutes of exposure.
- Concentrations: 8 concentrations tested in triplicate, up to 1000 µg/mL, or up to the solubility or cytotoxicity limit of the test item.
- Controls: vehicle as negative control, chlorpromazine as positive control.
- Endpoint: Neutral Red Uptake (NRU).
- Test item required: 100 mg.
Interpreting the result: the Photo-Irritation Factor
The main readout is the Photo-Irritation Factor (PIF): the ratio between the IC50 obtained without irradiation and the IC50 obtained with UV-A. The more a compound’s cytotoxicity increases under light, the higher the PIF. Results are interpreted using the prediction model of OECD 432, under which:
- a PIF below 2 predicts no phototoxic potential;
- a PIF between 2 and 5 predicts a probable phototoxic potential;
- a PIF above 5 predicts a phototoxic potential.
As with any in vitro result, the outcome is best read in context: together with the compound’s light absorption, its expected exposure in light-exposed tissues and the rest of the safety data, to decide whether further photosafety work is needed.
Why assess melanin binding?
Some compounds bind to melanin, the pigment found in the skin, the eye and hair. Binding can lead to accumulation and prolonged retention in pigmented tissues, which are also tissues exposed to light. Documenting melanin binding therefore helps refine the distribution part of a photosafety assessment.
Melanin binding is not, on its own, evidence of phototoxicity. It is one element of the overall picture, read alongside light absorption, photoreactivity and the results of phototoxicity testing.
The in vitro melanin binding assay
GenEvolutioN offers a straightforward in vitro melanin binding assay, run as a separate experiment from the 3T3 NRU phototoxicity test:
- Incubation: the test compound is incubated in buffer, in the presence and in the absence of synthetic melanin.
- Separation: the melanin fraction is separated after incubation.
- Quantification: the unbound compound remaining in the supernatant is measured by an appropriate analytical method, preferably HPLC or LC-MS/MS.
- Result: the apparent percentage of compound bound to melanin.
Depending on the objectives of the programme, the study can be extended to concentration-dependent binding and to binding reversibility, for a more complete characterisation of the compound’s interaction with melanin.
An initial feasibility phase is recommended first. It confirms the stability and solubility of the compound, its analytical recovery and the suitability of the experimental conditions before the full study starts. The final study design is defined with each sponsor according to its objectives.
A GLP framework for pharmaceutical dossiers
GenEvolutioN’s test facility is GLP-certified by the ANSM, the French health authority, and its regulatory in vitro toxicology studies are conducted in compliance with Good Laboratory Practice.
The 3T3 NRU phototoxicity test complements GenEvolutioN’s genotoxicity offering for pharmaceuticals, built around the ICH S2(R1) standard genotoxicity battery. Sponsors can thus address several in vitro safety endpoints of a drug candidate with a single partner.
Planning your photosafety study
- Test item: 100 mg for the 3T3 NRU phototoxicity test; the quantity for the melanin binding assay is defined during the feasibility phase.
- Timelines: confirmed at quotation stage, according to laboratory availability.
- Early contact: sharing the UV-visible absorption spectrum and solubility data at quotation stage helps define the right study design from the start.
Frequently asked questions
What is phototoxicity?
Is the 3T3 NRU phototoxicity test relevant for pharmaceuticals under ICH S10?
What does the Photo-Irritation Factor (PIF) mean?
Does melanin binding mean a compound is phototoxic?
How much test item is needed for a 3T3 NRU phototoxicity test?
Discuss your photosafety project
Need a GLP phototoxicity test for a drug candidate, with or without a melanin binding assay? Our team can review your compound’s properties and propose a study design aligned with ICH S10. Explore our GLP regulatory in vitro toxicology services or contact us to discuss your project.
Have a regulatory toxicology project?
Our team supports you across all your in vitro studies — OECD methods, REACH dossiers, biocides, cosmetics.
Discuss your project